Perspective Therapeutics (CATX) Receivables - Accured (2022 - 2025)

Perspective Therapeutics (CATX) has 3 years of Receivables - Accured data on file, last reported at $1.0 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Accured rose 16.25% year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2025 stood at $1.0 million (up 16.25% YoY), and the FY2025 full-year result was $1.0 million, up 16.25% from the prior year.
• Receivables - Accured climbed to $1.0 million in Q4 2025, from $880000.0 in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $1.0 million in Q4 2025 to a low of $109000.0 in Q4 2022.
• A 3-year average of $670666.7 and a median of $880000.0 in 2024 frame the typical range for Receivables - Accured.
• Peak annual rise in Receivables - Accured reached 16.25% in 2025, while the deepest fall reached 16.25% in 2025.
• Tracing CATX's Receivables - Accured over 3 years: stood at $109000.0 in 2022, then surged by 707.34% to $880000.0 in 2024, then increased by 16.25% to $1.0 million in 2025.
• Business Quant data shows CATX's Receivables - Accured at $1.0 million in Q4 2025, $880000.0 in Q4 2024, and $109000.0 in Q4 2022.